港股異動 | 開拓藥業-B漲超20%,普克魯胺可以抑制COVID-19男性患者的病情從輕度到重度轉變
uSMART盈立智投1月11日消息,週一港股早盤,開拓藥業-B高開高走,截至10:15分,開拓藥業-B盤中漲超20%。
開拓藥業-B此前發佈公告稱,發佈普克魯胺在治療COVID-19的臨牀試驗中男性患者的最終結果。最終結果顯示,普克魯胺可以顯著抑制感染COVID-19的男性患者的病情從輕度到重度轉變,並且對於短期給藥(15日)具有良好的安全性。集團亦在巴西開展針對感染COVID-19的女性患者的臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.